Woburn, Mass. – – September 29, 2026 -- Cytrellis Biosystems, Inc. has signed a commercialization agreement with KoreAx Co. Ltd. to launch its ellacor skin-removal device in South Korea, marking the company's second international market entry of 2026 after Australia.
South Korea's Ministry of Food and Drug Safety cleared ellacor in 2025
Ellacor is described as the first and only FDA-cleared, minimally invasive, in-office procedure that removes sagging skin without surgery or thermal energy. The device uses Micro-Coring technology and is approved for adults aged 22 and older with Fitzpatrick skin types I-IV.
Korean aesthetics market projected to nearly double to $1.1 billion by 2029
Independent market research cited by Cytrellis values South Korea's medical aesthetics sector at $572 million in 2023, with growth driven by demand for non-surgical treatments offering minimal downtime. Dr. Denise Dajles, President and CEO of Cytrellis, called the launch "a powerful stamp of approval" for the company's Micro-Coring technology in one of the world's most advanced and high-volume aesthetic markets.
KoreAx brings clinic network and key opinion leader access for market rollout
The partnership will handle training, education, and market penetration through KoreAx's existing relationships with clinics and industry specialists in Korea. Dr. Chang-Keun Oh, President of the Association of Korean Dermatologists, noted that ellacor has already been adopted in multiple countries with extended indications covering the neck, abdomen, and knee beyond facial applications.
Dual 2026 launches in Australia and Korea expand Cytrellis's global footprint
The Korean agreement follows Cytrellis's earlier 2026 launch in Australia, with the company stating both markets are intended to support continued procedure volume and revenue growth internationally.